BAUDETTE, Minn., Oct. 25, 2016 /PRNewswire/ -- ANI
Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the
launch of Benztropine Mesylate Tablets USP 0.5 mg, 1 mg and 2 mg.
The current annual U.S. market for this product is approximately
$25 million, according to IMS Health.
ANI will immediately launch the product.
Arthur S. Przybyl, ANI's
President and CEO stated, "Benztropine is the tenth new commercial
product introduction for ANI in 2016. We continue to pursue
expansion of our commercial portfolio via internal product
development, strategic partnerships, and acquisitions."
About Benztropine Mesylate Tablets USP
Benztropine Mesylate Tablets are indicated for use as an adjunct
in the therapy of all forms of parkinsonism and may also be useful
in the control of extrapyramidal disorders (except tardive
dyskinesia) due to neuroleptic drugs. For more information,
including the complete list of indications and usages, please see
the accompanying Full Prescribing Information.
About ANI
ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an
integrated specialty pharmaceutical company developing,
manufacturing, and marketing branded and generic prescription
pharmaceuticals. The Company's targeted areas of product
development currently include narcotics, oncolytics (anti-cancers),
hormones and steroids, and complex formulations involving extended
release and combination products. For more information, please
visit our website www.anipharmaceuticals.com.
Forward-Looking Statements
To the extent any statements made in this release deal with
information that is not historical, these are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited
to, statements about price increases, the Company's future
operations, products financial position, operating results and
prospects, the Company's pipeline or potential markets therefor,
and other statements that are not historical in nature,
particularly those that utilize terminology such as "anticipates,"
"will," "expects," "plans," "potential," "future," "believes,"
"intends," "continue," other words of similar meaning, derivations
of such words and the use of future dates.
Uncertainties and risks may cause the Company's actual results
to be materially different than those expressed in or implied by
such forward-looking statements. Uncertainties and risks include,
but are not limited to, the risk that the Company may face with
respect to importing raw materials; increased competition;
acquisitions; contract manufacturing arrangements; delays or
failure in obtaining product approval from the U.S. Food and Drug
Administration; general business and economic conditions; market
trends; products development; regulatory and other approvals and
marketing.
More detailed information on these and additional factors that
could affect the Company's actual results are described in the
Company's filings with the Securities and Exchange Commission,
including its most recent annual report on Form 10-K and quarterly
reports on Form 10-Q, as well as its proxy statement. All
forward-looking statements in this news release speak only as of
the date of this news release and are based on the Company's
current beliefs, assumptions, and expectations. The Company
undertakes no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
For more information about ANI, please contact:
Investor Relations
IR@anipharmaceuticals.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ani-pharmaceuticals-announces-launch-of-benztropine-mesylate-tablets-usp-300350034.html
SOURCE ANI Pharmaceuticals, Inc.